Risk of a second cancer and infection in patients with indolent B-cell lymphoma exposed to first-line bendamustine plus rituximab: A retrospective analysis of an administrative claims database.

Dote, Satoshi; Inose, Ryo; Goto, Ryota; Kobayashi, Yuka; Muraki, Yuichi

Dote, Satoshi; Inose, Ryo; Goto, Ryota; Kobayashi, Yuka; Muraki, Yuichi.

Afiliación

Dote S; Department of Pharmacy, Kyoto-Katsura Hospital, Kyoto, Japan.
Inose R; Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, Kyoto, Japan.
Goto R; Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, Kyoto, Japan.
Kobayashi Y; Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, Kyoto, Japan.
Muraki Y; Department of Pharmacy, Kyoto-Katsura Hospital, Kyoto, Japan.

Hematol Oncol ; 41(3): 354-362, 2023 Aug.

Article en En | MEDLINE | ID: mdl-36792059

Asunto(s)

Linfoma de Células B; Neoplasias Primarias Secundarias; Humanos; Rituximab; Clorhidrato de Bendamustina; Neoplasias Primarias Secundarias/inducido químicamente; Neoplasias Primarias Secundarias/epidemiología; Neoplasias Primarias Secundarias/tratamiento farmacológico; Estudios Retrospectivos; Estudios de Casos y Controles; Linfoma de Células B/etiología; Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos

Palabras clave

administrative claims database; bendamustine; indolent B-cell lymphoma; infection; second primary neoplasm

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfoma de Células B / Neoplasias Primarias Secundarias Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Hematol Oncol Año: 2023 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google